+90.9%
XLU vs MRNA
+554.4%
-463.5%
-36.1%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for all.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -0.3% | +5.4% | -5.7% | -0.4% |
| 7D | -1.6% | -1.1% | -0.5% | -1.6% |
| 30D | -3.3% | +126.1% | -129.4% | -5.7% |
| 3M | -3.2% | +190.0% | -193.2% | -6.4% |
| 6M | -7.0% | +157.2% | -164.2% | -9.8% |
| YTD | +0.6% | +388.2% | -387.6% | -4.5% |
| 1Y | +2.4% | +467.0% | -464.6% | -3.4% |
| 3Y | +46.3% | +36.1% | +10.2% | +42.1% |
| 5Y | +44.0% | -68.0% | +111.9% | +42.8% |
| All | +90.9% | +554.4% | -463.5% | +73.9% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over all: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
all analysis · Full analysis span regression · 6 months rolling